A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC

Christopher A. Lemmon, MD, a,* Gregory M. M. Videtic, MDCM, b Sudish Murthy, MD, PhD, c Kevin L. Stephans, MD, b Marc Shapiro, MD, a Usman Ahmad, MD, c Daniel Raymond, MD, c Vamsidhar Velcheti, MD, a, d Alejandro Bribriesco, MD, c Xuefei Jia, MS, e James Stevenson, MD, a Nathan A. Pennell, MD, PhD a

aDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
bDepartment of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
cDepartment of Thoracic and Cardiovascular Surgery, Cleveland Clinic Heart and Vascular Institute, Cleveland, Ohio
dPresent Address: Division of Hematology and Medical Oncology, Perlmutter Cancer Center, New York University Langone School of Medicine, New York, New York
eDepartment of Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio

Received 14 April 2022; revised 19 May 2022; accepted 4 June 2022
Available online - 15 June 2022

ABSTRACT

Introduction: Evidence supports the addition of immunotherapy to definitive chemoradiation for unresectable stage IIIA NSCLC. Adding pembrolizumab to neoadjuvant chemoradiation in patients with resectable stage IIIA NSCLC requires study for safety and feasibility.

Methods: Patients with resectable stage IIIA NSCLC received neoadjuvant cisplatin, etoposide, and pembrolizumab concurrently with thoracic radiotherapy of 45 Gy in 25 fractions. Patients without progression underwent resection followed by 6 months of consolidation pembrolizumab. Safety and feasibility were defined as less than or equal to 30% grade 3 or higher pulmonary toxicity or any grade 4 or 5 nonhematologic toxicity. A total of 10 patients were to be enrolled initially. If less than or equal to two patients had events, another 10 were to be enrolled.

Results: The study closed after enrolling nine patients. The median age was 66 (range: 49–76) years. A total of 67% were female. Median follow-up was 38.3 months. Serious adverse events occurred in seven patients, including two grade 5 events: one sudden cardiac arrest in the neoadjuvant phase and one fatal pneumocystis pneumonia after resection. Eight patients were assessable for response. The overall response rate was 67%. Six underwent complete resection. Four achieved pathologic complete response, whereas one additional patient had complete nodal clearance. Median progression-free survival has not been reached. The 3-year overall survival was 64%.

Conclusions: Adding pembrolizumab to neoadjuvant concurrent cisplatin, etoposide, and radiotherapy in resectable stage IIIA NSCLC resulted in an encouraging pathologic complete response rate. Higher-than-expected toxicities
necessitated trial closure after meeting the rule for infeasibility. The relationship of grade 5 events to the addition of pembrolizumab is unclear.

© 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Neoadjuvant; Chemoradiation; Immunotherapy; NSCLC

Introduction

NSCLC remains one of the most prevalent cancers and one of the deadliest cancers in the United States. Of the newly diagnosed patients each year, approximately 20% to 30% will present with locally advanced disease with lymph node involvement. The goal of treatment in these patients remains cure, but only approximately 30% of these patients achieve long-term survival, with most recurring and ultimately having a poor outcome.1

For patients deemed capable of undergoing surgical resection of their cancer, neoadjuvant chemotherapy has been studied suggesting similar benefit when given either before resection or in the adjuvant setting.2 For those with locally advanced disease, trimodality therapy with the addition of concurrent radiation to chemotherapy before surgery was found to have a progression-free survival (PFS) benefit over chemoradiation (CRT) alone, on the basis of data from the Intergroup 0139 trial, and was also effectively used for management of Pancoast tumors in the S9416 trial.3,4 Nevertheless, recurrence and outcomes in this group remain poor and the need for new therapies or treatment paradigms is paramount.

The introduction of monoclonal antibody immune checkpoint inhibitor (ICI) therapy to the treatment of advanced-stage NSCLC has dramatically improved survival outcomes in this population.5 In addition, a subgroup analysis of KEYNOTE-001, which tested ICI in advanced disease, suggested an improvement in PFS and overall survival (OS) in patients receiving pembrolizumab who had previously received radiation treatment compared with those who had no previous radiation.6

This observation has been explained by the hypothesis of radiation-induced immunogenic cellular death. This phenomenon initially leads to activation of the immune system with increased antigen presentation and lymphocyte infiltration, but over time it leads to immune exhaustion. This in turn leads to up-regulation of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), causing an immunosuppressive environment. Treatment with an anti–PD-1 or anti–PD-L1 ICI is thought to counter this immunosuppressive state and allow more durable immunostimulatory responses to radiation.7,8 ICI therapy added to radiation therapy has also been observed to have benefits owing to the abscopal effect, in which increased efficacy and cancer response are noted outside of the radiation field.9,10

In testing the role of immunotherapy in earlier stages of NSCLC, the PACIFIC trial enrolled patients with locally advanced unresectable NSCLC and found improved survival outcomes with the addition of one year of consolidation anti–PD-L1 therapy after standard CRT.11 More recently, several studies have evaluated the use of neoadjuvant ICI in different combinations in the neoadjuvant setting revealing promising results, particularly in major pathologic response and complete response rates.12,13

From this, it is reasonable to question whether the addition of ICI therapy to radiation therapy in the neoadjuvant setting could have additional benefit in the locally advanced, resectable population. Nevertheless, ICIs and radiation are known to independently increase the risk of pneumonitis, so the potential additive effect of this combination needs to be further elucidated to determine the incidence, severity, and possible consequences on the treatment course.

Herein, we present the results of a phase 1 study of the addition of the anti–PD-1 ICI pembrolizumab to neoadjuvant concurrent CRT followed by surgery and consolidation pembrolizumab for treatment in patients with stage IIIA resectable NSCLC with the hypothesis that this regimen would be both safe and feasible.

Materials and Methods

Study Population

This study enrolled patients aged more than or equal to 18 years old, with biopsy-confirmed stage IIIA (T1-3N2M0) NSCLC (adenocarcinoma, squamous cell carcinoma, large cell, or NSCLC NOS) according to the American Joint Committee on Cancer eighth edition with measurable or unmeasurable disease on the basis of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. All patients underwent pathologic mediastinal nodal staging before enrollment. Additional eligibility requirements included adequate performance status with an Eastern Cooperative Oncology Group score of 0 to 1, adequate lung and organ function for treatment, and no contraindications to pembrolizumab. Eligible patients had to have been deemed surgically resectable by a thoracic surgeon and not received previous treatment for this cancer diagnosis. Patients were also requested to provide archival tissue from a tumor lesion or undergo new biopsy if tissue was unavailable.

Study participants were assigned to one of five different dose levels of pembrolizumab for neoadjuvant therapy: 100, 200, 400, 800, or 1600 mg every 3 weeks. All patients received chemotherapy with carboplatin and paclitaxel. An additional three patients were enrolled at dose levels of 3200 and 6400 mg every 3 weeks, which are not reported here. Three patients were enrolled at a dose level of 1600 mg every 6 weeks, which are also not reported here. pembrolizumab was continued adjuvant therapy until disease progression on the basis of RECIST 1.1 criteria or unacceptable toxicity.
Exclusion criteria included previous treatment for the currently diagnosed cancer, a diagnosis of immunodeficiency or receiving systemic steroid therapy within seven days of the initial trial treatment, active autoimmune disease requiring systemic treatment within the last 2 years (excluding replacement therapy), history of active tuberculosis, or known additional malignancy requiring active treatment. Also excluded are those who were pregnant, breastfeeding, or expecting to conceive; those with a history of human immunodeficiency virus, active hepatitis B, or hepatitis C; and those who have received a live vaccine within 30 days.

All patients were required to sign informed consent to participate in the study.

Study Design

At the time of conceptualization, pembrolizumab had been safely added to platinum-doublet chemotherapy, but had not been tested concurrently with radiation therapy in NSCLC. Therefore, this phase 1 non-randomized safety and feasibility study was designed on the basis of the risk of developing grade 3 or higher pulmonary toxicity. Ten patients were to be enrolled initially at full doses of all three systemic agents. If three or more (≥30%) had grade 3 or higher pulmonary toxicity, or any grade 4 nonhematologic toxicity, the study was to be stopped. If two or fewer had grade 3 or higher pulmonary toxicity or grade 4 or higher non-pulmonary toxicity, then an additional 10 patients were to be enrolled for a total population of 20. Participants would be followed during the treatment period and during surveillance for up to five years after treatment. The protocol was approved by the local institutional review board and carried out in accordance with the Declaration of Helsinki. The trial was registered with ClinicalTrials.gov number NCT02987998. Funding for the trial was provided by Merck.

End Points

The primary end point of safety was defined as the feasibility of delivering concurrent neoadjuvant chemoradiotherapy with pembrolizumab on the basis of the rate of pulmonary toxicity. If five or fewer (<20%) of the expected 20 patients enrolled developed grade 3 or higher pulmonary toxicity or grade 4 or higher nonhematologic toxicity, then the regimen was to be deemed safe and feasible for further study.

Secondary end points included PFS, objective response rate, complete pathologic response (pCR) rate, nodal downstaging at surgery, OS, and safety and tolerability. Radiographic response to treatment, including progression, was determined by investigator assessment using RECIST 1.1 criteria.

Toxicity Monitoring

Adverse event grading was performed according to Common Terminology Criteria for Adverse Events version 4.0. Serious adverse events for this trial were defined as any event that results in death, is life threatening, results in persistent or substantial disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a new cancer, is an overdose, or is another important medical event that may jeopardize the subject and may require intervention to prevent one of the previously listed outcomes.

Statistical Analysis

Analyses for safety and feasibility were descriptive. OS was calculated from the start date of treatment to the date of last follow-up or death, and PFS was calculated from the start date of treatment to the first recurrence or progression or death. Kaplan-Meier method was used to evaluate both OS and PFS. We determined the probability of stopping early if the true rate of unacceptable toxicity is more than or equal to 30% was 62% but only

Treatment Plan

Patients were to receive concurrent induction CRT with all systemic agents being given intravenously (IV). Chemotherapy with cisplatin and etoposide was chosen based off of the Intergroup 0139 trial of neoadjuvant concurrent chemoradiotherapy. Cisplatin 50 mg/m² IV was to be given on days 1, 8, 29, and 36 and etoposide 50 mg/m² IV on days 1 to 5 and days 29 to 33. Thoracic radiotherapy consisted of a total dose of 45 Gy in 25 fractions beginning on day 1 of chemotherapy. In addition, patients were to receive pembrolizumab 200 mg IV on days 1, 22, and 43. Four weeks after completion of the induction course, patients were to be assessed for radiographic response to therapy by RECIST 1.1 criteria. Those with progressive disease were to be taken off study. Patients with resectable disease without progression were to undergo resection within two weeks of assessment and within six weeks of completion of induction treatment. If patients were deemed inoperable at the time of assessment for medical, anatomical, or reasons other than progressive disease, they would complete definitive radiotherapy to a total dose of 61 Gy concurrent with consolidation pembrolizumab. Consolidation pembrolizumab 200 mg IV was to be given every 21 days for 6 months (9 cycles) and was to start no more than 90 days after surgery (or within 30 d of being deemed inoperable). The six-month adjuvant pembrolizumab course was chosen to establish to a total treatment course of approximately one year.
7% if the true rate is less than 30%. The overall likelihood of rejecting this regimen as infeasible if it is too toxic was estimated to be 81% and 9% if it is truly feasible. All statistical analyses were performed using R Statistical Software (version 4.1.3; R Foundation for Statistical Computing, Vienna, Austria).

Results

A total of nine patients were enrolled in the study. Initial patient enrollment was in March 2017, and final data were analyzed in November 2021. Enrollment was halted with early termination of the study owing to higher-than-expected toxicity (Fig. 1). Surveillance of the enrolled participants continued after study closure. Patient demographics can be found in Table 1, with a median age of 66 (range: 49–76) years and with 67% of patients being female.

Most of the patients received the planned neoadjuvant treatment with concurrent pembrolizumab and CRT. One patient expired during the neoadjuvant phase owing to sudden cardiac arrest. The other eight patients were assessable for radiographic response after completion of induction treatment. One patient had radiologic progression of disease and was taken off study. Another patient was found to have progressive pleural and pericardial metastases at the time of resection, and surgery was aborted. The remaining six patients (75%) had a partial radiographic response to treatment and subsequently underwent surgical resection. All patients had surgical lobectomy and mediastinal lymph node dissection, with four patients undergoing

![Image](CONSORT-diagram.png)

**Figure 1.** CONSORT diagram. AKI, acute kidney injury; IV, intravenously; PJP, *Pneumocystis jirovecii* pneumonia; SBRT, stereotactic body radiation therapy.
Thoracotomy and two patients undergoing video-assisted thoracoscopic surgery. Complete resection was achieved in all six of these patients. Four of the six (67%) had a pCR in the resected specimen with no residual viable cancer in the primary tumor or lymph nodes. One additional patient had complete nodal clearance of malignancy with small residual primary tumor. One patient did not achieve primary tumor response or nodal downstaging in the completely resected specimen (Table 2).

Four patients received at least one treatment of consolidation pembrolizumab. Of the nine total initial patients enrolled, two died before reaching this stage of the planned treatment, two patients progressed, and one patient was unable to receive consolidative therapy owing to grade 3 pneumonitis. Three of the four who received consolidation pembrolizumab completed the entire 6-month regimen. One patient elected to forego further treatment after three cycles related to progressive dyspnea from long-standing chronic obstructive pulmonary disease.

At the time of analysis, the median follow-up was 38.3 months. Median PFS had not been reached. PFS at 6 months was 55.6% (95% confidence interval: 31%-99%) with no change at the 3-year mark. At the time of analysis for most recent follow-up, no patient who underwent complete resection had disease recurrence. Median OS had not been reached. The three-year OS rate was 64% (95 confidence interval: 39%-100%) (Fig. 2).

### Toxicities

A total of 14 serious adverse events as defined previously were reported in seven of nine patients (Table 3). Two grade 5 events occurred and included one episode of sudden cardiac arrest during the neoadjuvant phase, attributed to history of coronary artery disease, and one episode of *Pneumocystis jirovecii* pneumonia (PJP) occurring more than 60 days after resection and full surgical recovery, and before initiation of consolidation pembrolizumab, ultimately leading to hypoxic respiratory failure. This pneumonia occurred despite the patient only receiving steroid premedication for chemotherapy induced nausea in the neoadjuvant setting and the patient being human immunodeficiency virus negative.

Other events of note during the neoadjuvant phase included one patient with colon perforation owing to diverticulosis with abscess formation, further complicated by ileal stenosis and necessitating a partial colectomy. Owing to this, the patient did not receive the final dose of cisplatin, pembrolizumab, or the last fraction of radiation in neoadjuvant treatment before proceeding to response assessment.

Events in the postoperative setting included an episode of pneumothorax with hypoxia after complex Pancoast resection. After re-exploration, a suspected bronchopleural fistula was repaired. This patient later developed a chest wall hematoma causing severe tachycardia and requiring evacuation. A second patient underwent resection with a postoperative complication of a loculated pleural effusion with empyema formation, which was then decorticated and attributed to grade 3 pneumonitis. One additional episode of grade 1 pneumonitis occurred in a separate patient, with both fully recovering.

The most common additional adverse events included blood count abnormalities, including an

---

**Table 1. Patient Demographics**

| Patients | N = 9 |
|----------|-------|
| Age, y  | Median = 66 | Range 49-76 |
| Sex     | M = 3 | 33 |
|         | F = 6 | 66 |
| Race    | White = 9 | 100 |
| ECOG    | 0 = 6 | 66 |
|         | 1 = 3 | 33 |
| Initial T stage | T1x = 3 | 3 |
|          | T2x = 6 | 66 |
| Nonsquamous | 7 | 77 |
| Squamous | 2 | 22 |
| PD-L1 status | Low (≤1%-49%) = 6 | 66 |
|          | High (≥50%) = 2 | 22 |
|         | Not tested = 1 | 11 |

ECOG, Eastern Cooperative Oncology Group; F, female; M, male; PD-L1, programmed death-ligand 1.

**Table 2. Results and Outcomes**

| Patients | N = 9 |
|----------|-------|
| Completed neoadjuvant treatment | 7/9 | 77 |
| Assessed for response | 8/9 | 88 |
| ORR | 6/8 | 67 |
| PD | 2/8 | 25 |
| PR | 6/8 | 75 |
| Complete resection | 6/8 | 75 |
| pCR | 4/6 | 67 |
| pH0 | 5/6 | 83 |
| pHx | 1/6 | 17 |
| Adjuvant pembrolizumab | 4/8 | 50 |
| Median follow-up | 38.3 mo |
| 6-mo PFS | 55.6% | 95% CI: 31%-99% |
| Median PFS | Not reached |
| 3-y OS | 64% | 95% CI: 39%-100% |
| Median OS | Not reached |

*Including pCR.

CI, confidence interval; ORR, objective response rate; OS, overall survival; pCR, complete pathologic response; PD, progressive disease; PFS, progression-free survival; pH0, pathologic node negative; pHx, pathologic node positive; PR, partial response.
Discussion

This phase 1 safety and feasibility study was the first designed to combine ICI therapy with pembrolizumab concurrently with CRT in the neoadjuvant setting for NSCLC. This treatment protocol led to an encouraging pCR rate in this small population compared with traditional neoadjuvant strategies using CRT alone, suggesting that if tolerable this strategy could hold promise. Unfortunately, there was higher-than-expected toxicity observed in this study necessitating early closure. This was triggered by meeting the technical rule for stopping and infeasibility, having recorded two grade 5 events. Nevertheless, these events could not definitively be attributed to the addition of pembrolizumab to the standard CRT treatment regimen. This study used a concurrent chemotherapy backbone of cisplatin and etoposide on the basis of the Intergroup 0139 trial that has been found to have higher rates of adverse events than other regimens, and this may have contributed to the resulting toxicity profile, but again, the relationship to grade 5 events is unclear. Study of concurrent ICI and CRT with an alternative established chemotherapy regimen is underway and may provide further insight into the safety and efficacy of this strategy.

Exploring the association of toxicities, the patient who expired owing to sudden cardiac arrest was known to have a history of coronary artery disease before enrollment, and it is unlikely that the addition of pembrolizumab aggravated this. Nevertheless, either the chemotherapy alone or the combination with the pembrolizumab may have been responsible for the acute kidney injury that developed the week before, and the contribution of this to his cardiac arrest is unknown.

With regard to the second grade 5 event of PJP causing hypoxic respiratory failure, there are rare case reports in patients of this occurring when they have been treated with pembrolizumab, but the association is not firmly established and thus difficult to ascertain causality. When PJP is found with the use of ICIs, it is most often owing to the use of high-dose steroids for treatment of immune-related adverse events. This patient had received no such treatment.

Diverticular colon perforation with ICI therapy has no clear association to the use of PD-1– or PD-L1–inhibiting agents, and no relation can be made regarding the addition of pembrolizumab to this event.

Intraoperative complications by subjective description were as expected. There was noted adhesive tissue of fibrosis in four of six patients undergoing resection, consistent with findings of response to treatment. Other
Additional data were recently released revealing safety and efficacy of adding pembrolizumab to CRT without unexpected safety concerns.19 Early data in resectable NSCLC have primarily focused on using neoadjuvant immunotherapy either alone or in combination with chemotherapy, and these have revealed promising findings, especially with improvements in pCR rate compared with neoadjuvant chemotherapy alone.12,13,20 Additional data were recently released revealing an improvement in event-free survival with neoadjuvant chemoimmunotherapy, leading to the approval of the Food and Drug Administration for the neoadjuvant setting.18 Pneumonitis occurred at a rate and with toxicity that was not limiting to the trial progress.

Table 4. Most Common Adverse Events (Any Grade)

| Most Common Adverse Events | Number Affected, n/N (%) |
|----------------------------|--------------------------|
| Anemia                     | 8/9 (88)                 |
| Thrombocytopenia           | 4/9 (44)                 |
| Lymphopenia                | 9/9 (100)                |
| Neutropenia                | 8/9 (88)                 |
| Constipation               | 5/9 (55)                 |
| Diarrhea                   | 4/9 (44)                 |
| Nausea                     | 7/9 (77)                 |
| LFT abnormalities          | 4/9 (44)                 |
| Hypoalbuminemia            | 8/9 (88)                 |
| Hypomagnesemia             | 6/9 (66)                 |
| Hyponatremia               | 4/9 (44)                 |
| Fatigue                    | 8/9 (88)                 |
| Radiation dermatitis       | 4/9 (44)                 |
| Alopecia                   | 7/9 (77)                 |

LFT, liver function test.

In conclusion, this first study of concurrent pembrolizumab added to neoadjuvant CRT in the treatment of locally advanced, stage IIIA NSCLC required early closure because it met the rule for infeasibility owing to the occurrence of two grade 5 events. The relationship of toxicity to the addition of pembrolizumab or choice of chemotherapy is unclear. This protocol found a promising pathologic complete response rate in this small phase 1 trial. The patients who have undergone resection seem to have achieved durable remissions. The small patient population analyzable, the need for early study closure, and the limited number of patients completing consolidation treatment preclude the ability to evaluate any role for ICI on outcomes in this treatment approach. Additional studies underway should provide additional clarity to these results.

CRediT Authorship Contribution Statement

Nathan A. Pennell, James Stevenson, Alejandro Bribiesco, Vamsidhar Velcheti, Daniel Raymond, Usman Ahmad, Marc Shapiro, Kevin L. Stephens, Sudish Murthy, Gregory M. M. Videtic: Conceptualization, Methodology.

Christopher A. Lemmon, Xuefei Jia, Nathan A. Pennell: Data curation, Formal analysis.

Christopher A. Lemmon, Gregory M. M. Videtic, Sudish Murthy, Kevin L. Stephens, Marc Shapiro, Usman Ahmad, Daniel Raymond, Vamsidhar Velcheti, Alejandro Bribiesco, Xuefei Jia, James Stevenson, Nathan A. Pennell: Investigation, Manuscript writing and editing, Final approval of manuscript.
Acknowledgments
This investigator-initiated trial was funded by Merck.

References
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33.
2. Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 2009;4:1380-1388.
3. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomized controlled trial. Lancet. 2009;374:379-386.
4. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemotherapy and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007;25:313-318.
5. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemoradiotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-1830.
6. Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial [published correction appears in Lancet Oncol. 2017;18:e371]. Lancet Oncol. 2017;895-903.
7. Sato H, Okonoji N, Nakano T. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol. 2020;25:801-809.
8. Gong X, Li X, Jiang T, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2017;12:1085-1097.
9. Reyners K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41:503-510.
10. Siva S, Callahan J, MacManus MP, Martin O, Hicks RJ, Ball DL. Abscopal effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer. J Thorac Oncol. 2013;8:e71-e72.
11. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
12. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976-1986.
13. Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413-1422.
14. Roy SF, Louie AV, Liberman M, Wong P, Bahig H. Pathologic response after modern radiotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(suppl 2):S124-S134.
15. Steuer CE, Behera M, Ernani V, et al. Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer: a systematic review. JAMA Oncol. 2017;3:1120-1129.
16. Hong MH, Ahn B, Kim HR, et al. FP03.02 interim analysis of neoadjuvant chemoradiotherapy and durvalumab for potentially resectable stage III non-small cell lung cancer (NSCLC). J Thorac Oncol. 2021;16:S194-S195.
17. Si S, Erickson K, Evageliou N, et al. An usual presentation of Pneumocystis jirovecii pneumonia in a woman treated with immune checkpoint inhibitor. J Pediatr Hematol Oncol. 2020;10:1097.
18. Brouchet L, Bauvin E, Marcheix B, et al. Impact of induction treatment on postoperative complications in the treatment of non-small cell lung cancer. J Thorac Oncol. 2007;2:626-631.
19. Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab plus concurrent chemoradiotherapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 2021;7:1-9.
20. Ulas EB, Dickhoff C, Schnieders FL, Senan S, Bahce I. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. ESMO Open. 2021;6:100244.
21. Food and Drug Administration. FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung. Accessed March 21, 2022.
22. Romero Román A, Campo-Cañaveral de la Cruz JL, Macía I, et al. Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer. Eur J Cardiothor Surg. 2021;60:81-88.
23. Spicer J, Wang C, Tanaka F, et al. Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl):8503-8503.
24. Hellmann MD, Chaft JE, William WN Jr, et al. Pathologic response after neoadjuvant chemoradiation in resectable non-small-cell lung cancers: proposal for the use of major pathologic response as a surrogate endpoint. Lancet Oncol. 2014;15:e42-e50.
25. Hamada A, Soh J, Hata A, et al. Phase II study of neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable stage IIIA-B (Discrete N2) non-small-cell lung cancer: SQUAT trial (WJOG 12119L). Clin Lung Cancer. 2021;22:596-600.
26. Dickhoff C, Senan S, Schnieders FL, et al. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. BMC Cancer. 2020;20:764.